NCT06026501View on ClinicalTrials.gov

A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

PE0116,PE0105

"1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug"

All Listed Sponsors

collaborator

Shanghai HyaMab Biotech Co.,Ltd.

INDUSTRY

lead

Shanghai YingLi Pharmaceutical Co. Ltd.

INDUSTRY

NCT06026501 - A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | Biotech Hunter | Biotech Hunter